Medicare Embraces the Skinny Trend: Wegovy Now Covered!
Staff Editor
2 min read
Medicare’s potential decision to cover the weight-loss treatment drug Wegovy has been making waves, according to a recent report from the Wall Street Journal. This drug, which has been gaining popularity, especially among celebrities, could soon become more accessible to a wider population if Medicare’s coverage extends to it. However, not every Medicare member may qualify for this coverage. As per the report, only individuals with a history of heart disease who intend to use Wegovy for preventing heart attacks and strokes might have their treatments covered by insurance.
Wegovy, known as semaglutide in the pharmaceutical world, received approval from the Food and Drug Administration in 2021. Medicare, a federal health insurance program for Americans over 65 and younger individuals with disabilities, has historically not covered obesity treatments under its Part D drug-benefit plans. While some Part D plans already cover drugs like Ozempic and Mounjaro, which contain a similar active ingredient as Wegovy for diabetes treatment, they have not extended coverage to obesity management.
The cost of obesity drug treatments, such as Wegovy, can be exorbitant, ranging from $900 to $1,300 per month without insurance. This high price point has made these treatments financially out of reach for many individuals. However, experts anticipate that with increased competition from other obesity drug manufacturers entering the market, prices may begin to decline. Additionally, Medicare’s potential coverage of Wegovy could open up avenues for negotiations on pricing under President Joe Biden’s Inflation Reduction Act, as reported by Reuters.
By potentially covering Wegovy, Medicare could significantly impact millions of individuals struggling with heart disease and weight management. Juliette Cubanski, the deputy director of the Medicare policy program, highlighted the possibility of Medicare patients with both conditions receiving coverage for this drug due to its heart health benefits, NBC News reported. This development could potentially revolutionize access to effective weight-loss treatments for a broader demographic, bringing hope to many who have been unable to afford such medications in the past.
As the landscape of healthcare evolves, the inclusion of Wegovy under Medicare coverage could mark a significant step forward in combating obesity and its related health issues. With increased affordability and access to innovative treatments, individuals could see improvements not only in their heart health but also in their overall well-being. The potential coverage of Wegovy by Medicare underscores the importance of addressing obesity as a critical health concern that requires attention, resources, and support for those affected.
